EGPA is traditionally treated using glucocorticoids, either alone or in combination with conventional immunosuppressants. Mepolizumab, a novel anti-interleukin (IL)-5 agent, has been approved as an add-on therapy for adult patients with EGPA. The recommended dose of mepolizumab is 300 mg (...
hours; leukotriene receptor antagonists (LTRAs), such as montelukast or zafirlukast; slow-release theophylline; long-acting muscarinic receptor antagonists (LAMAs) such as tiotropium bromide or glycopyrronium bromide; with biologics such as omalizumab, mepolizumab, reslizumab, benralizumab, or ...